Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Which drug stops preterm labor best? new study pits nifedipine against magnesium sulfate

NCT ID NCT05343806

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two drugs—nifedipine (a pill) and magnesium sulfate (given through a vein)—to see which is better at delaying preterm labor in pregnant women between 32 and 36 weeks. A total of 264 women took part, and the main goal was to see how many avoided giving birth within 48 hours of starting treatment. The hope is that delaying labor gives time for steroids to help the baby's lungs develop, reducing health risks for newborns.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nifedipine and magnesium sulfate
What this could lead to
If one drug works better, it could help more women delay preterm labor long enough for steroids to mature the baby's lungs, reducing newborn complications.
What could go wrong
This is a single-center trial with 264 participants, so results may not apply to all pregnant women. Both drugs have side effects like low blood pressure or breathing issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

264 people

The number who actually took part.

Started

Apr 2023

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Pregnant women with threatened preterm labor defined as 3 or more uterine contractions in 30 minutes confirmed by cardiotocography. 2. Gestational age from 32 week + 0 days to (inclusive) 36 weeks + 0 days. 3. Women with singleton or multiple pregnancy. 4. Women with preterm prelabor rupture of membranes (PROM) will be included if they have uterine contractions. Exclusion Criteria: 1. Contraindications for the use of either drugs, such as cardiac disease, hypotension, myasthenia gravis, or renal impairment. 2. Contraindications for tocolysis, such as intrauterine demise, intrauterine infection, fetal distress, placental separation, or severe pre-eclampsia. 3. Cervical dilatation \> 5 cm. 4. Cervical length \> 30 mm by trans-vaginal ultrasound. 5. Cervical cerclage.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Threatened preterm labor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Faculty of Medicine, Assiut University

    Asyut, Asyut Governorate, 71515, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.